Aliases & Classifications for Paraplegia

MalaCards integrated aliases for Paraplegia:

Name: Paraplegia 12 75 53 44 15 17 72
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 53
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD9CM 35 344.1
MeSH 44 D010264
NCIt 50 C50687
SNOMED-CT 68 60389000
ICD10 33 G82.2 G82.20
UMLS 72 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 10 and spastic paraplegia 49, autosomal recessive, and has symptoms including ophthalmoplegia, hemiplegia and paraparesis. An important gene associated with Paraplegia is SPAST (Spastin), and among its related pathways/superpathways is Endocytosis. The drugs Acetazolamide and Succinylcholine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone and brain, and related phenotypes are no effect and behavior/neurological

Wikipedia : 75 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1147)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 10 34.8 SPAST KIF5A
2 spastic paraplegia 49, autosomal recessive 34.7 ZFYVE26 SPG7 SPG11
3 spastic paraplegia 11, autosomal recessive 34.4 SPG7 SPG21 SPG11
4 spastic paraplegia 46, autosomal recessive 34.2 SPG21 SPG11
5 spastic paraplegia 15, autosomal recessive 34.2 ZFYVE26 SPG7 SPG21 SPG11
6 spastic paraplegia 20, autosomal recessive 34.1 SPG7 SPART
7 spastic paraplegia 61, autosomal recessive 34.1 SPAST RTN2 REEP1 ATL1
8 spastic paraplegia 24, autosomal recessive 34.1 SPG7 SPG21 CYP7B1
9 spastic paraplegia 32, autosomal recessive 34.0 SPG7 SPG21 SPG11 ATL1
10 spastic paraplegia 54, autosomal recessive 34.0 RTN2 DDHD1
11 spastic paraplegia 28, autosomal recessive 33.9 RTN2 DDHD1
12 spastic paraplegia 44, autosomal recessive 33.9 ZFYVE27 SPG21 SLC33A1
13 spastic paraplegia 2, x-linked 33.8 ZFYVE27 RTN2 REEP1 PLP1 ATL1
14 spastic paraplegia 52, autosomal recessive 33.8 RTN2 DDHD1
15 mast syndrome 33.8 SPG21 SPG11
16 spastic paraplegia 31, autosomal dominant 33.6 ZFYVE27 SPG11 SPAST RTN2 REEP1 ATL1
17 spastic paraplegia 10, autosomal dominant 33.6 ZFYVE27 SPG11 RTN2 REEP1 KIF5A ATL1
18 spastic paraplegia 39, autosomal recessive 33.5 ZFYVE26 WASHC5 REEP1 ERLIN2
19 spastic paraplegia 47, autosomal recessive 33.5 WASHC5 REEP1 ERLIN2
20 spastic paraplegia 3, autosomal dominant 33.5 ZFYVE27 SPG11 SPAST RTN2 REEP1 NIPA1
21 masa syndrome 33.3 SPG11 SPAST SPART REEP1 NIPA1 ATL1
22 spastic paraplegia 35, autosomal recessive 33.2 ZFYVE26 SPG21 SPG11 ERLIN2
23 spastic paraplegia 48, autosomal recessive 33.2 ZFYVE26 SPG21 SPG11 ERLIN2
24 spastic paraplegia 13, autosomal dominant 33.2 WASHC5 SPAST HSPD1 ERLIN2 ATL1
25 spastic paraplegia 33, autosomal dominant 33.2 ZFYVE27 SPAST SPART RTN2 REEP1
26 spastic paraplegia 8, autosomal dominant 33.1 WASHC5 SPG11 REEP1 NIPA1 ERLIN2 ATL1
27 spastic paraplegia 42, autosomal dominant 33.1 WASHC5 SLC33A1 REEP1 NIPA1 ERLIN2
28 primary lateral sclerosis, adult, 1 33.0 SPG7 SPAST
29 spastic paraplegia 30, autosomal recessive 32.9 WASHC5 SPG21 REEP1 KIF1A ERLIN2
30 spastic paraplegia 18, autosomal recessive 32.9 WASHC5 SPG21 REEP1 NIPA1 ERLIN2
31 spastic paraplegia 6, autosomal dominant 32.7 SPAST SLC33A1 REEP1 NIPA1 KIF5A ERLIN2
32 spastic paraplegia 12, autosomal dominant 32.4 ZFYVE27 SPAST RTN2 REEP1 KIF5A ERLIN2
33 spasticity 32.2 WASHC5 SPG7 SPAST KIF1A DDHD1
34 leukodystrophy, hypomyelinating, 4 31.8 PLP1 HSPD1
35 spastic paraplegia 4, autosomal dominant 31.6 ZFYVE27 SPG7 SPG11 SPAST SLC33A1 RTN2
36 spastic paraparesis 31.0 SPG7 SPG11 SPAST DDHD1
37 hereditary spastic paraplegia 27.5 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG21 SPG11
38 spastic paraplegia 7, autosomal recessive 12.8
39 spastic paraplegia 17, autosomal dominant 12.7
40 spastic paraplegia, optic atrophy, and neuropathy 12.7
41 spastic paraplegia 72, autosomal recessive 12.7
42 spastic paraplegia 23, autosomal recessive 12.6
43 spastic paraplegia 5a, autosomal recessive 12.6
44 spastic paraplegia 11 12.6
45 spastic paraplegia 56, autosomal recessive 12.6
46 spastic paraplegia 45, autosomal recessive 12.6
47 spastic paraplegia 43, autosomal recessive 12.6
48 spastic paraplegia 15 12.6
49 spastic paraplegia 57, autosomal recessive 12.6
50 spastic paraplegia 55, autosomal recessive 12.6

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


ophthalmoplegia, hemiplegia, paraparesis, paraplegia, ataxic, monoparesis, paraplegia, cerebral, paraplegia, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid

GenomeRNAi Phenotypes related to Paraplegia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ATL1 CYP7B1 DDHD1 ERLIN2 HSPD1 KIF1A

MGI Mouse Phenotypes related to Paraplegia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 ATL1 HSPD1 KIF1A KIF5A PLP1 REEP1
2 nervous system MP:0003631 9.32 HSPD1 KIF1A KIF5A PLP1 REEP1 SLC33A1

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Succinylcholine Approved Phase 4 306-40-1 5314
3 Natriuretic Agents Phase 4
4 diuretics Phase 4
5 Anticonvulsants Phase 4
6 Carbonic Anhydrase Inhibitors Phase 4
7 Neuromuscular Agents Phase 4
8 Neuromuscular Depolarizing Agents Phase 4
9 Neuromuscular Blocking Agents Phase 4
10
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
11
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
12
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
13
4-Aminopyridine Approved Phase 3 504-24-5 1727
14 Cortivazol Investigational Phase 3 1110-40-3
15 Anti-Bacterial Agents Phase 2, Phase 3
16 Anti-Infective Agents Phase 2, Phase 3
17 Lipid Regulating Agents Phase 2, Phase 3
18 Hypolipidemic Agents Phase 2, Phase 3
19 Antimetabolites Phase 2, Phase 3
20 Neurotransmitter Agents Phase 2, Phase 3
21 Cholinergic Agents Phase 2, Phase 3
22 Acetylcholine Release Inhibitors Phase 2, Phase 3
23 Botulinum Toxins Phase 2, Phase 3
24 Potassium Channel Blockers Phase 3
25
Resveratrol Approved, Experimental, Investigational Phase 2 501-36-0 445154
26
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
27
Atorvastatin Approved Phase 2 134523-00-5 60823
28
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
29
Levodopa Approved Phase 1, Phase 2 59-92-7 6047
30
Carbidopa Approved Phase 1, Phase 2 28860-95-9 34359
31
Buspirone Approved, Investigational Phase 1, Phase 2 36505-84-7 2477
32 Protamines Phase 2
33 Antineoplastic Agents, Phytogenic Phase 2
34 Cathartics Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 2
36 Antioxidants Phase 2
37 Analgesics, Non-Narcotic Phase 2
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
39 Protective Agents Phase 2
40 Laxatives Phase 2
41 Platelet Aggregation Inhibitors Phase 2
42 Anticholesteremic Agents Phase 2
43 Antirheumatic Agents Phase 2
44 abobotulinumtoxinA Phase 2
45 Pharmaceutical Solutions Phase 2
46 Hemagglutinins Phase 2
47 incobotulinumtoxinA Phase 2
48 Botulinum Toxins, Type A Phase 2
49 Dopamine Agents Phase 1, Phase 2
50 Serotonin Receptor Agonists Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
2 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
3 Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine Completed NCT02425449 Phase 4 Succinylcholine
4 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
5 Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica - Controlled Randomized Trial With Double Blind Evaluation Unknown status NCT02151045 Phase 3
6 Activity-Dependent Plasticity After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
7 Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study Completed NCT02604186 Phase 2, Phase 3
8 Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network Completed NCT00614744 Phase 2, Phase 3
9 An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI Completed NCT02455336 Phase 2, Phase 3 Fenofibrate
10 Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial Not yet recruiting NCT03899584 Phase 3 4-Aminopyridine;Placebo oral capsule
11 A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayedstart Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients Not yet recruiting NCT03935724 Phase 2, Phase 3
12 Optimizing Cooling Strategies at < 6 Hours of Age for Neonatal Hypoxic-Ischemic Encephalopathy Terminated NCT01192776 Phase 3
13 A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3 Cethrin (BA-210);Placebo
14 Randomised Open Study of the Efficiency and Tolerance of the Use of a Corset on the Respiratory Function of Spinal Cord Injury Patients Withdrawn NCT01569360 Phase 3
15 Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury Unknown status NCT02326662 Phase 1, Phase 2
16 Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest Unknown status NCT02542306 Phase 2 fibrinogen concentrate
17 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Completed NCT02314208 Phase 2 Xenbilox;Tahor
18 Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study Completed NCT03961906 Phase 2
19 Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin) in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2 Xeomin;Botox®
20 A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury Completed NCT00500812 Phase 1, Phase 2 Cethrin
21 Electrical Stimulation Induced Lower Limb Exercise Capacity, Cardiorespiratory Response, Cardiovascular Risk Factors and Muscle Activity Patterns in Response to Robotic Assisted Treadmill Gait Training in Individuals With Complete Motor Spinal Cord Injury Completed NCT01349478 Phase 1, Phase 2
22 Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury Completed NCT01484184 Phase 1, Phase 2 SPINALON (buspirone + levodopa + cardidopa)
23 Exoskeleton Training After Spinal Cord Injury Recruiting NCT03410550 Phase 2
24 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury:A Multicenter, Prospective, Cohort Study Recruiting NCT03505034 Phase 2 Umbilical Cord Mesenchymal Stem Cells
25 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury:A Multicenter, Randomized, Controlled Trial Recruiting NCT03521336 Phase 2 Umbilical Cord Mesenchymal Stem Cells;Placebo
26 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury:A Multicenter, Randomized, Controlled Trial Recruiting NCT03521323 Phase 2 Umbilical Cord Mesenchymal Stem Cells;Placebos
27 Randomized Clinical Trial for the Evaluation of Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Not yet recruiting NCT02574585 Phase 2
28 A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
29 A Prospective, Randomised, Controlled, Open Study. Phase II Treatment Equivalent. Terminated NCT00429013 Phase 2
30 Rehabilitation of the Lower Extremity With AMES Following Incomplete Spinal Cord Injury (SCI) Terminated NCT01498991 Phase 1, Phase 2
31 Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection (RAID): Study Protocol for Randomized Controlled Trial Unknown status NCT03001739 Phase 1 Urapidil Hydrochloride Injection
32 Orthostatic Tolerance During FES-evoked Stepping in Paraplegia: A Safety and Viability Study Completed NCT00108043 Phase 1
33 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI) Completed NCT01739023 Phase 1
34 Use of Interactive Gaming After Spinal Cord Injury Completed NCT01537978 Phase 1
35 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation Completed NCT02354625 Phase 1
36 Improving Ambulatory Community Access After Paralysis Recruiting NCT01570816 Phase 1
37 Tissue Bonding Cystostomy(TBC) Not yet recruiting NCT01771159 Phase 1
38 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Unknown status NCT01454570
39 Computationally Quantifying Wheelchair Set-Up to Minimize Peak Shoulder Joint Forces Throughout Manual Wheelchair Propulsion: A Pilot Study Unknown status NCT00785278
40 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
41 NSC Assistive Technology Research: Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407
42 Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair Unknown status NCT02774096 xenon
43 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
44 Early Intervention to Reduce Bone Loss After Spinal Cord Injury Unknown status NCT02334410
45 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630
46 Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Radiculopathy Associated to Lumbar Disk Disease. Two Years Follow-up Unknown status NCT02185508
47 Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829
48 Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI) Unknown status NCT02559804
49 Assessment of Home/Work Simulation Tasks and Community Mobility Skills in the ReWalk Powered Exoskeleton in Persons With Spinal Cord Injury Unknown status NCT02118194
50 Abdominal Functional Electrical Stimulation to Augment Breathing in Tetraplegia Unknown status NCT00202631

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

41
Spinal Cord, Bone, Brain, Heart, Prostate, Testes, Skin

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 12072)
# Title Authors PMID Year
1
CNB-001 reduces paraplegia in rabbits following spinal cord ischemia. 38
31397359 2019
2
Intraoperative Computed Tomography Navigation-Assisted Resection of Symptomatic Intramedullary Spinal Cord Cavernoma: A Technical Note and Case Report. 38
31229746 2019
3
Patient Reported Bladder Related Symptoms and Quality of Life after Spinal Cord Injury with Different Bladder Management Strategies. 38
30958741 2019
4
Excess burden of a chronic disabling condition: life lost due to traumatic spinal cord injury in a Swiss population-based cohort study. 38
31147730 2019
5
The Effect of Prophylactic Hypothermia on Neurophysiological and Functional Measures in the Setting of Iatrogenic Spinal Cord Impact Injury. 38
31158549 2019
6
Open distal anastomosis in the frozen elephant trunk technique: initial experiences and preliminary results of arch zone 2 versus arch zone 3†. 38
30932147 2019
7
Intrafamilial variable spastic paraplegia/ataxia/ALS phenotype linked to a novel KIF5A mutation. 38
31286494 2019
8
Whole exome sequencing identifies novel variant underlying hereditary spastic paraplegia in consanguineous Pakistani families. 38
31281085 2019
9
An analysis of the causes of transient paraplegia during percutaneous vertebral augmentation under local anesthesia: A case series of 12 patients. 38
31354044 2019
10
'I am free in my wheelchair but pain does have a say in it though': The meaning and experience of quality of life when living with paraplegia and chronic pain. 38
29284303 2019
11
The end of "Cutting for Stone"? Using the lithoclast trilogy for cystolitholapaxy on a 4 cm bladder stone per urethra. 38
31338304 2019
12
Cross-cultural validation of a Brazilian version of the adapted manual wheelchair circuit (AMWC-Brazil). 38
29659301 2019
13
FARS2 Causing Complex Hereditary Spastic Paraplegia With Dysphonia: Expanding the Disease Spectrum. 38
31106652 2019
14
Patient perspectives of Internet-delivered cognitive behavior therapy for psychosocial issues post spinal cord injury. 38
30958020 2019
15
Hybrid Off-pump Second-Stage Aortic Arch Repair after Type A Dissection. 38
30243266 2019
16
Survivals of the Intraoperative Motor-evoked Potentials Response in Pediatric Patients Undergoing Spinal Deformity Correction Surgery: What Are the Neurologic Outcomes of Surgery? 38
30882759 2019
17
Multiple spinal chronic subdural hematomas associated with thoracic hematomyelia: a case report and literature review. 38
31394354 2019
18
Spinal Cord Ischemia after Endovascular Aortic Repair of a Unilateral Iliac Artery Dissecting Aneurysm: A Case Report. 38
30684624 2019
19
Paraplegia due to spinal cord ischemia after endovascular treatment of a type II endoleak. 38
31394248 2019
20
Novel Machine Learning Approach to Identify Preoperative Risk Factors Associated With Super-Utilization of Medicare Expenditure Following Surgery. 38
31411664 2019
21
Complexity of Generating Mouse Models to Study the Upper Motor Neurons: Let Us Shift Focus from Mice to Neurons. 38
31394733 2019
22
Poor adherence to influenza vaccination guidelines in spinal cord injury: results from a community-based survey in Switzerland. 38
31371803 2019
23
Is admission to an SCI specialized rehabilitation facility associated with better functional outcomes? Analysis of data from the Thai Spinal Cord Injury Registry. 38
30842632 2019
24
Independent Influence of Spinal Cord Injury Level on Thermoregulation during Exercise. 38
30865188 2019
25
Evaporative heat loss insufficient to attain heat balance at rest in individuals with a spinal cord injury at high ambient temperature. 38
31414956 2019
26
POEMS syndrome: A rare paraneoplastic presentation of spinal plasmacytoma. 38
31424045 2019
27
Peer mentoring reduces unplanned readmissions and improves self-efficacy following inpatient rehabilitation for individuals with spinal cord injury. 38
31403374 2019
28
Healthcare-associated urinary tract infections with onset post hospital discharge. 38
31217038 2019
29
Interrater and intrarater reliability of ventilatory thresholds determined in individuals with spinal cord injury. 38
30820032 2019
30
A unilateral less invasive posterolateral approach for disc debridement and titanium cage insertion supplemented by contralateral transfascial screw fixation for high-morbidity patients suffering from septic thoracolumbosacral spondylodiscitis. 38
30993521 2019
31
Physician-Modified Thoracic Stent Grafts for the Arch After Surgical Treatment of Type A Dissection. 38
30898563 2019
32
Clinical outcomes of the Seal® thoracic stent graft for traumatic aortic injury in a Korean multicenter retrospective study. 38
31394246 2019
33
Early Experience with the Octopus Endovascular Strategy in the Management of Thoracoabdominal Aneurysms. 38
31394231 2019
34
Commentary: Does the risk of paraplegia leave you cold? 38
31176546 2019
35
[Effects of Clinical Characteristics, Laboratory Parameters and Treatment Regimens on Prognosis of Patients with Multiple Myeloma]. 38
31418374 2019
36
A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination. 38
31231989 2019
37
Endovascular Repair of Ascending Aortic Pathologies With Tubular Endografts: A Single-Center Experience. 38
31140362 2019
38
A patient with juvenile-onset refractory status epilepticus caused by two novel compound heterozygous mutations in FARS2 gene. 38
31329004 2019
39
Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing. 38
31104286 2019
40
Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism. 38
31433872 2019
41
P5CS expression study in a new family with ALDH18A1-associated hereditary spastic paraplegia SPG9. 38
31402623 2019
42
Hereditary spastic paraplegia and prominent sensorial involvement: think MAG mutations! 38
31402626 2019
43
Paraplegia as an initial manifestation of pancreatic cancer. 38
31406932 2019
44
A case of spastic paraplegia-15 with a novel pathogenic variant in ZFYVE26 gene. 38
31385551 2019
45
A novel mutation in SPART gene causes a severe neurodevelopmental delay due to mitochondrial dysfunction with complex I impairments and altered pyruvate metabolism. 38
31314595 2019
46
Biophysical characterization Of Alpers encephalopathy associated mutants of human mitochondrial phenylalanyl-tRNA synthetase. 38
31241862 2019
47
Untreated distal intimal tears may be associated with paraplegia after total arch replacement and frozen elephant trunk treatment of acute Stanford type A aortic dissection. 38
30396731 2019
48
Late open conversion after thoracic endovascular aortic repair. 38
30691702 2019
49
Technical aspects and 30-day outcomes of the prospective early feasibility study of the GORE EXCLUDER Thoracoabdominal Branched Endoprosthesis (TAMBE) to treat pararenal and extent IV thoracoabdominal aortic aneurysms. 38
30612825 2019
50
Retrospective study of functional outcomes and disability after non-ischaemic vascular causes of spinal cord dysfunction. 38
31403383 2019

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 ZFYVE27 WASHC5 SPG21 SPART KIF5A

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.91 ZFYVE27 WASHC5 SPAST SLC33A1 RTN2 REEP1
2 endoplasmic reticulum membrane GO:0005789 9.76 ZFYVE27 SPAST SLC33A1 RTN2 REEP1 ERLIN2
3 axon GO:0030424 9.62 ZFYVE27 SPG11 KIF1A ATL1
4 midbody GO:0030496 9.58 ZFYVE26 SPAST SPART
5 endoplasmic reticulum tubular network GO:0071782 9.13 ZFYVE27 REEP1 ATL1
6 axon cytoplasm GO:1904115 8.92 SPG7 SPAST KIF5A KIF1A
7 cytoplasm GO:0005737 10.18 ZFYVE27 ZFYVE26 WASHC5 SPG21 SPG11 SPAST

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle transport GO:0048489 9.16 SPG11 KIF5A
2 retrograde neuronal dense core vesicle transport GO:1990049 8.96 KIF5A KIF1A
3 anterograde axonal transport GO:0008089 8.8 SPG7 SPAST KIF1A

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity GO:0016887 9.26 SPAST KIF5A KIF1A HSPD1
2 ATP-dependent microtubule motor activity, plus-end-directed GO:0008574 9.16 KIF5A KIF1A
3 microtubule binding GO:0008017 8.92 SPAST REEP1 KIF5A KIF1A

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....